Adds valuation target in paragraph 1, details on IPO throughout
Jan 21 (Reuters) - China-based Ascentage Pharma 6855.HK said on Tuesday it was targeting a valuation of $1.75 billion in its initial public offering in the United States.
Ascentage, backed by Japan's biggest drugmaker Takeda Pharmaceutical 4502.T, is seeking $149 million by offering about 7.3 million American depositary shares at $20.34 each.
J.P.Morgan and Citigroup are the underwriters for the offering.
Ascentage will list on the Nasdaq under the symbol "AAPG".
(Reporting by Arasu Kannagi Basil in Bengaluru; Editing by Shounak Dasgupta)
((ArasuKannagi.Basil@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。